- Home
- MGNX vs PANL Comparison
MGNX vs PANL Comparison
Compare MGNX & PANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- PANL
- Stock Information
- Founded
- MGNX 2000
- PANL 1996
- Country
- MGNX United States
- PANL United States
- Employees
- MGNX N/A
- PANL N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- PANL Marine Transportation
- Sector
- MGNX Health Care
- PANL Consumer Discretionary
- Exchange
- MGNX Nasdaq
- PANL Nasdaq
- Market Cap
- MGNX 257.3M
- PANL 289.9M
- IPO Year
- MGNX 2013
- PANL N/A
- Fundamental
- Price
- MGNX $3.24
- PANL $5.87
- Analyst Decision
- MGNX Buy
- PANL Strong Buy
- Analyst Count
- MGNX 11
- PANL 1
- Target Price
- MGNX $8.57
- PANL N/A
- AVG Volume (30 Days)
- MGNX 770.4K
- PANL 183.3K
- Earning Date
- MGNX 11-05-2024
- PANL 11-12-2024
- Dividend Yield
- MGNX N/A
- PANL 6.81%
- EPS Growth
- MGNX N/A
- PANL N/A
- EPS
- MGNX N/A
- PANL 0.47
- Revenue
- MGNX $141,329,000.00
- PANL $521,238,386.00
- Revenue This Year
- MGNX $119.63
- PANL $6.40
- Revenue Next Year
- MGNX N/A
- PANL $15.67
- P/E Ratio
- MGNX N/A
- PANL $12.42
- Revenue Growth
- MGNX 16.68
- PANL 5.23
- 52 Week Low
- MGNX $2.95
- PANL $5.77
- 52 Week High
- MGNX $21.88
- PANL $9.53
- Technical
- Relative Strength Index (RSI)
- MGNX 37.79
- PANL 33.84
- Support Level
- MGNX $3.61
- PANL $5.77
- Resistance Level
- MGNX $5.10
- PANL $6.80
- Average True Range (ATR)
- MGNX 0.35
- PANL 0.19
- MACD
- MGNX -0.10
- PANL -0.06
- Stochastic Oscillator
- MGNX 4.62
- PANL 9.71
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About PANL Pangaea Logistics Solutions Ltd.
Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk transportation services. It transports drybulk cargos including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The firm's services include cargo loading, cargo discharge, vessel chartering, voyage planning and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters.